Market Access & Pricing in the EU

Detailed programme 25 March - 13:00 - 17:00
29 April - 13:00 - 17:00
27 May - 13:00 - 17:00
10 June - 13:00 - 17:00 13:00 - 17:00 25 March 2021 - Market Access and Pricing in France & Italy
13:00 - 15:00 Graham Foxon, Remap Consulting UK Ltd 25 March 2021 Market Access & Pricing in France

Stakeholder in France

HTA process and the role of RWE in the HTA context

Pricing negociation with CEPS; Value based pricing approaches?

Managed Access Entry Agreements & Patient Access Schemes; role of ATU

Specialties with regard to ATMPs/Gentherapeutics

Price, volume & revenues forecasting

15:00 - 17:00 Dr Entela Xoxi,School of Health Economics and Management (ALTEMS) 25 March 2021 Market Access & Pricing in Italy

Stakeholder in Italy - nationally and regionally

Managed Access Entry Agreements & Patient Access Schemes

Role of RWE in the HTA context

Specialties with regard to ATMPs/Gentherapeutics/Orphan drugs

Value based pricing approaches

Price, volume & revenues

13:00 - 17:00 29 April 2021 - Market Access and Pricing in Germany and the UK
13:00 - 15:00 Graham Foxon, Remap Consulting UK Ltd & Partner 29 April 2021 Market Access & Pricing in UK

Stakeholder & Stakeholder mapping post Brexit

Managed Access Entry Agreements & Patient Access Schemes

Role of RWE in the HTA context

Specialties with regard to ATMPs/Gentherapeutics/Orphan drugs

Value based pricing approaches

Price, volume & revenues

15:00 - 17:00 Thomas Ecker, Ecker und Ecker GmbH 29 April 2021 Market Access & Pricing in Germany

The AMNOG process 2021 - role of RWE?

Challenge AbDe

Managed Access Entry Agreements & Patient Access Schemes - what is possible

Price, volume & revenues

Value based pricing approaches

13:00 - 17:00 27 May 2021 - Market Access and Pricing in Spain & Scandinavia
13:00 - 15:00 Christian Hill, MAP BioPharma Limited & Partners 27 May 2021 Market Access & Pricing in Spain

Stakeholder in Spain - nationally and regionally

HTA process and the role of RWE in the HTA context

Negociation with SGCMPS

Managed Access Entry Agreements & Patient Access Schemes

Specialties with regard to ATMPs/Gentherapeutics/Orphan drugs

Price, volume & revenues forecasting

15:00 - 17:00 Christian Hill, MAP BioPharma Limited & Partners 27 May 2021 - Market Access and Pricing in Scandinavia & Denmark

Stakeholder & Stakeholder mapping

Managed Access Entry Agreements & Patient Access Schemes

Role of RWE in the HTA context

Pricing & Forecasting

Specialties with regard to ATMPs/Gentherapeutics/Orphan drugs

13:00 - 17:00 10 June 2021 - EU-trends in Market Access & Pricing
13:00 - 15:00 Christian Hill, MAP BioPharma Limited & Partners 10 June 2021 - EU-HTA and further supranational initiatives

EUnetHTA

BeneLuxA

15:00 - 17:00 Karen Piontek, Simon & Kucher 10 June 2021 - EU-Tendering

European tender for hospitals/ hospital chains

Cross country tenders - upcoming trends

Detailed programme 25 March - 13:00 - 17:00
29 April - 13:00 - 17:00
27 May - 13:00 - 17:00
10 June - 13:00 - 17:00 13:00 - 17:00 25 March 2021 - Market Access and Pricing in France & Italy
13:00 - 15:00 Graham Foxon, Remap Consulting UK Ltd 25 March 2021 Market Access & Pricing in France

Stakeholder in France

HTA process and the role of RWE in the HTA context

Pricing negociation with CEPS; Value based pricing approaches?

Managed Access Entry Agreements & Patient Access Schemes; role of ATU

Specialties with regard to ATMPs/Gentherapeutics

Price, volume & revenues forecasting

15:00 - 17:00 Dr Entela Xoxi,School of Health Economics and Management (ALTEMS) 25 March 2021 Market Access & Pricing in Italy

Stakeholder in Italy - nationally and regionally

Managed Access Entry Agreements & Patient Access Schemes

Role of RWE in the HTA context

Specialties with regard to ATMPs/Gentherapeutics/Orphan drugs

Value based pricing approaches

Price, volume & revenues

13:00 - 17:00 29 April 2021 - Market Access and Pricing in Germany and the UK
13:00 - 15:00 Graham Foxon, Remap Consulting UK Ltd & Partner peutics/Orphan...